The global Aptamers market size was estimated at USD 1,624.9 million in 2021 and is expected to surpass around USD 10.15 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 23.9% during the forecast period 2022 to 2030.
Key Takeaways:
- By Application, the U.S. Aptamers market was valued at USD 670 million in 2021 and expected to witness growth at a CAGR of 22.9% from 2022 to 2030.
- The nucleic acid aptamers segment dominated the market in 2021. The segment is set to grow at a rapid pace into areas such as therapeutics, diagnostics, research and development consumables, and biomarker discovery
- The research and development segment dominated the market in 2021 due to the growing interest of companies in aptamers; moreover, the rising awareness level coupled with favorable government initiatives are expected to stimulate the market growth of this applications segment during the study period
- The diagnostics segment is expected to be the fastest-growing segment during the forecast period due to the rising demand for aptamer-based diagnostic kits for the early diagnosis of diseases. For instance, in July 2021, SomaLogic and the CM Life Sciences announced the supply of 7,000-plex SomaScan Assay kits & SomaScan data to Beth Israel Deaconess Medical Center (BIDMC) for proteomics research
- North America dominated the market in 2021 due to the presence of key biopharmaceutical companies such as SomaLogic, IVERIC Bio, Inc., Aptagen LLC, Base Pair Biotechnologies, and their strategic initiatives for the development of new aptamers
Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages, including small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies may fuel the R&D of novel aptamers, thereby driving the market growth.
The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such as non-small cell lung cancer, solid tumors, and renal cancer.
In addition, initiatives undertaken by regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, and CDSCO to support the research and development in the field of aptamers are projected to fuel market growth. For instance, in March 2020, IVERIC Bio, Inc. received Fast Track designation from the U.S. FDA for Zimura for the treatment of patients with GA secondary to age-related macular degeneration (AMD). Zimura is a chemically synthesized pegylated RNA aptamer, administered by intravitreal injection. It acts by inhibiting complement factor C5 which is responsible for the development of AMD.
Companies are studying aptamers for applications such as western blotting, ELISA, therapeutics, and flow cytometry. Custom aptamer selection is considered to be an important service offered by existing aptamer players to life sciences companies. Thrombin aptamers, cocaine aptamers, and theophylline aptamers are some of the most frequently used customized aptamers for research and development activities. Thus, the surge in numbers of biotech and pharma companies working on research related to aptamers and related technologies has opened up new avenues for the growth of this market.
Moreover, there are a number of strategic initiatives undertaken by key players such as mergers & acquisitions, with an aim to expand their current aptamer product portfolio. For instance, in May 2022, Epicore Biosystems acquired Eccrine Systems' intellectual property and assets. This acquisition boosts Epicore’s wearable microfluidic solutions with additional aptamer-based sweat sensor technology from the Eccrine Systems and the University of Cincinnati to its aptamer product portfolio and strengthens the company’s position in the market. This aptamers-based sensor has been demonstrated in stress, pain, and other healthcare management applications.
Report Scope of the Aptamers Market
Type Insights
The nucleic acid segment dominated the market and held the largest revenue share of 77.8% in 2021, and is expected to witness the highest growth during the forecast period. At present, many companies are investigating the mechanism of action of nucleic acid aptamers for the treatment of various disorders, including age-related macular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted a written agreement under Special Protocol Assessment (SPA) to IVERIC BIO (formerly known as Ophthotech Corporation) for the design of GATHER2 phase 3 clinical trial of Zimura for treatment of patients with GA secondary to AMD. This approval is expected to boost segment growth.
The peptide aptamer segment is expected to witness lucrative market growth over the forecast period owing to the large application base for diagnostic and therapeutic purposes. For instance, in August 2021, scientists from the Engineering Center for Microtechnology and Diagnostics developed a novel biosensor for multiparametric express testing in preclinical diagnostics of cardiovascular disease. Next-generation biochips have been developed for this testing based on the peptide aptamer marker system and molecular recognition. For this, researchers have designed peptide aptamers using data from Data Bank and Protein 3D software. Hence, the introduction of such products in the market may boost the utilization of peptide aptamers.
Application Insights
The research and development segment dominated the market and held the highest revenue share of 30.9% in 2021. The growth of the segment is attributed to the rising demand for aptamers, coupled with increasing research activities in this field. There are various strategic initiatives undertaken by key players like collaborations, partnerships, and agreements for the R&D of novel aptamers-based diagnostic and therapeutic products. For instance, in June 2021, SomaLogic and Ixaka Ltd entered into a research collaboration with an aim to support the discovery and development of aptamers-based bispecific therapeutics. This collaboration evaluates the safety and efficacy of antigen-specific SOMAmer reagents. Such an initiative is expected to boost segment growth.
The therapeutics segment is expected to exhibit lucrative market growth during the forecast period, owing to the ability to design antidotes rationally (which is tough with antibodies) and is considered to be the better alternative related to protein therapeutics in terms of synthetic accessibility, size, and modification by medicinal chemistry. These all facts will collectively help the therapeutics segment to build a strong market presence during the future period. However, nuclease resistance is a major threat associated with therapeutic aptamers, which may restrain segment growth.
Regional Insights
North America dominated the aptamers market and accounted for the largest revenue share of 44.9% in 2021. The rising prevalence of chronic diseases, strong healthcare infrastructure, and the growing interest of research laboratories in the aptamer field are some of the major factors for the dominance of the region. In April 2022, Noxxon Pharma announced that it will present top-line result data for its NOX-A12 GLORIA trial in brain cancer at the 2022 American Society of Clinical Oncology annual meeting.
In Asia Pacific, the market is expected to be the fastest-growing during the forecast period. The growth of the region is attributable to the approval of new aptamer-based products in the region. For instance, in April 2020, Achiko AG entered into an agreement with the Pengurus Wilayah Nahdlatul Ulama DKI, a Jakarta-based world's largest Islamic association for the marketing and sales of aptamer-based COVID-19 diagnostic kit AptameX. This organization has 90 million registered members in Indonesia.
Some of the prominent players in the Aptamers Market include:
- SomaLogic
- Aptamer Group
- Aptamer Sciences, Inc.
- Base Pair Biotechnologies
- Noxxon Pharma
- Vivonics Inc.
- Aptagen, LLC
- TriLink Biotechnologies
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Aptamers market
- Application
- Diagnostics
- Therapeutics
- Research And Development
- Others
- Technology
- End-user
- Pharmaceutical & Biotechnology Companies
- Academic & Government Research Institutes
- CROs
By Geography
North America
Europe
- Germany
- France
- United Kingdom
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
Key Points Covered in Aptamers Market Study:
- Growth of Aptamers in 2022
- Market Estimates and Forecasts (2017-2030)
- Brand Share and Market Share Analysis
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Recommendation on Key Winning Strategies
- COVID-19 Impact on Demand for Aptamers and How to Navigate
- Key Product Innovations and Regulatory Climate
- Aptamers Consumption Analysis
- Aptamers Production Analysis
- Aptamers and Management
Request Customization
Get a Sample
Get a Sample
Request Customization